Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite

References

• Atalla A, Breyer-Pfaff U, Maser E. (2000). Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol. Xenobiotica 30:755–69
   PubMed Web of Science ®Google Scholar
• Atalla A, Maser E. (2001). Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact 130:737–48
   PubMed Web of Science ®Google Scholar
• Bauman DR, Rudnick SI, Szewczuk LM, et al. (2005). Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol Pharmacol 67:60–8
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32
   PubMed Web of Science ®Google Scholar
• Botta L, Gerber HU, Schmid K. (1985). Measurement of radioactivity in biological experiments. In: Garrett ER, Hirtz JL, eds. Drug fate and metabolism, methods and techniques. New York: Marcel Dekker Inc., 99–134
   Google Scholar
• Bousquet-Melou A, Laffont CM, Laroute V, Toutain PL. (2002). Modelling the loss of metabolic capacities of cultured hepatocytes: application to measurement of Michaelis–Menten kinetic parameters in in vitro systems. Xenobiotica 32:895–906
   PubMed Web of Science ®Google Scholar
• EMA. (2012). Guideline on the investigation of drug interactions. London, UK: European Medicines Agency, Committee for Human Medicinal Products (CHMP)
   Google Scholar
• FDA. (2008). Guidance for industry: safety testing of drug metabolites. Silver Spring (MD): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)
   Google Scholar
• FDA. (2012). Drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. Silver Spring: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)
   Google Scholar
• Gebel T, Maser E. (1992). Characterization of carbonyl reducing activity in continuous cell-lines of human and rodent origin. Biochem Pharmacol 44:2005–12
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1996). In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 24:521–33
   PubMedGoogle Scholar
• ICH. (2009). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Geneva, Switzerland: International Conference on Harmonisation (ICH)
   Google Scholar
• Jamieson SMF, Gu Y, Manesh DM, et al. (2014). A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. Biochem Pharmacol 88:36–45
   PubMed Web of Science ®Google Scholar
• Malatkova P, Maser E, Wsol V. (2010). Human carbonyl reductases. Curr Drug Metab 11:639–58
   PubMed Web of Science ®Google Scholar
• Newton DJ, Wang RW, Lu AYH. (1995). Cytochrome-P450 inhibitors – evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver-microsomes. Drug Metab Dispos 23:154–8
   PubMed Web of Science ®Google Scholar
• Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–9
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Usuki E, Yerino P, Parkinson A. (2008). In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (Reaction phenotyping) with emphasis on cytochrome P450. In: Rodrigues AD, ed. Drug-drug interactions. 2nd ed. New York: Informa Healthcare, 231–358
   Google Scholar
• Oppermann U. (2007). Carbonyl reductases: the complex relationships of mammalian carbonyland quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol 47:293–322
   Google Scholar
• Palackal NT, Lee SH, Harvey RG, et al. (2002). Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells. J Biol Chem 277:24799–808
   PubMed Web of Science ®Google Scholar
• Pyonteck SM, Akkari L, Schuhmacher AJ, et al. (2013). CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19:1264–72
   PubMed Web of Science ®Google Scholar
• Rowbotham SE, Boddy AV, Redfern CPF, et al. (2010). Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metab Dispos 38:1261–6
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome-P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic-chemicals – studies with liver-microsomes of 30 Japanese and 30 caucasians. J Pharmacol Exp Ther 270:414–23
   PubMed Web of Science ®Google Scholar
• Stanley ER, Berg KL, Einstein DB, et al. (1997). Biology and action of colony-stimulating factor-1. Mol Reprod Dev 46:4–10
   PubMed Web of Science ®Google Scholar
• Stresser DM, Broudy MI, Ho T, et al. (2004). Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32:105–12
   PubMed Web of Science ®Google Scholar
• Sutton J, Wiesmann M, Huh K, et al. (2010). Discovery of a selective CSF-1R inhibitor. Abstracts of Papers, 239th ACS National Meeting; MEDI-33; 2010 March 21–25; San Francisco (CA)
   Google Scholar
• Tong Z, Chandrasekaran A, Li HS, et al. (2010). In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone. Drug Metab Dispos 38:801–7
   PubMed Web of Science ®Google Scholar
• Totah RA, Rettie AE. (2005). Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance (vol 77, p 341, 2005). Clin Pharmacol Ther 78:153 [Erratum]
   Web of Science ®Google Scholar
• Tucker GT, Houston JB, Huang SM. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential – towards a consensus. Br J Clin Pharmacol 52:107–17
   PubMed Web of Science ®Google Scholar
• Varatharajan S, Abraham A, Zhang W, et al. (2012). Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur J Clin Pharmacol 68:1577–86
   PubMed Web of Science ®Google Scholar
• Wang T, Papoutsi M, Wiesmann M, et al. (2011). Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics. Int J Toxicol 30:300–12
   PubMed Web of Science ®Google Scholar
• Wiesmann M, Daniel DL, Pryer N, et al. (2010). Abstract 3629: BLZ945, a selective c-fms (CSF-1R) kinase inhibitor for the suppression of tumor-induced osteolytic lesions in bone. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research (AACR), Apr 17–21, 2010, Washington, DC, United States. Cancer Res 70(8 Suppl):Abstract number 3629
   Google Scholar
• Yeo KR, Rostami-Hodjegan A, Tucker GT. (2004). Abundance of cytochromes P450 in human liver: a meta-analysis. Br J Clin Pharmacol 57:687–8
   Web of Science ®Google Scholar
• Zhang YY, Liu Y, Zhang JW, et al. (2009). Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 39:283–92
   PubMed Web of Science ®Google Scholar
• Zhu DM, Hua L. (2010). How carbonyl reductases control stereoselectivity: approaching the goal of rational design. Pure Appl Chem 82:117–28
   Web of Science ®Google Scholar